Artificial Intelligence driven Marketing Communications
Xceleron Ltd entered administration (chapter 11) on January 10th 2012 with debts of 7m. It provided bioanalytical accelerator mass spectrometry (AMS) services for drug development. It conducted microdosing, pre-clinical evaluation, intravenous pharmacokinetics, metabolite profiling, and mass balance investigations in humans. The company served the pharmaceutical and biotechnology markets. Xceleron Ltd was formerly known as The Centre for Biomedical Accelerator Mass Spectrometry Ltd. and changed its name to Xceleron Ltd in 2003. The company was founded in 1997 and was headquartered in York, the United Kingdom with a facility in Maryland.